Prolonged response to recombinant human erythropoietin treatment in patients with myelodysplastic syndrome at a single referral centre in Brazil

Autor: Anna Thawanny Gadelha Moura, Maritza Cavalcante Barbosa, Fernando Barroso Duarte, Romélia Pinheiro Gonçalves Lemes, Talyta Ellen de Jesus dos Santos
Jazyk: angličtina
Předmět:
Male
Time Factors
Kaplan-Meier Estimate
030204 cardiovascular system & hematology
Síndromes Mielodisplásicas
Hemoglobins
0302 clinical medicine
Reference Values
Risk Factors
hemic and lymphatic diseases
Epoetina alfa
030212 general & internal medicine
Response rate (survey)
Aged
80 and over
lcsh:R5-920
Medical record
General Medicine
Middle Aged
Progression-Free Survival
Treatment Outcome
International Prognostic Scoring System
Eritropoetina
Recombinant Human Erythropoietin
Disease Progression
Original Article
Female
lcsh:Medicine (General)
Brazil
medicine.drug
medicine.medical_specialty
Karyotype
Myelodysplastic Syndrome
03 medical and health sciences
Internal medicine
medicine
Humans
In patient
Blood Transfusion
Erythropoietin
Aged
Retrospective Studies
business.industry
Platelet Count
Retrospective cohort study
EPO Alfa
Epoetin Alfa
Myelodysplastic Syndromes
Referral centre
Hematinics
business
Who classification
EPO
Zdroj: Clinics, Vol 74
Clinics
Clinics, Volume: 74, Article number: e771, Published: 09 SEP 2019
Clinics; v. 74 (2019); e771
Clinics; Vol. 74 (2019); e771
Universidade de São Paulo (USP)
instacron:USP
Repositório Institucional da Universidade Federal do Ceará (UFC)
Universidade Federal do Ceará (UFC)
instacron:UFC
ISSN: 1980-5322
1807-5932
Popis: OBJECTIVES: To evaluate the effects of epoetin (EPO) alfa treatment on overall survival, event-free survival and response duration in patients with myelodysplastic syndrome (MDS) who were treated at a haematological referral centre in northeastern Brazil. METHODS: This was a retrospective cohort study of 36 patients diagnosed with MDS and treated with EPO alfa at 30,000 to 60,000 IU per week. Clinical data were collected from medical records. The events assessed were non-response to treatment and progression to acute myeloid leukaemia (AML). Statistical analyses were performed using GraphPad Prism 7 and SPSS 24 software. RESULTS: The overall survival of patients who received EPO alfa treatment was 51.64%, with a median of 65 months of treatment, and the overall survival of this group was 100% during the first 24 months. We detected a 43.5-month median event-free survival, with a response rate of 80.5%. We observed responses from 25 to 175 months. Patients with transfusion dependence and those with a high-risk stratification, as determined by the International Prognostic Scoring System (IPSS), the Revised International Prognostic Scoring System (IPSS-R), the WHO classification-based Prognostic Scoring System (WPSS) and the WHO 2016, had a lower event-free survival than other patients. CONCLUSIONS: Despite the wide use of EPO alfa in the treatment of anaemia in patients with MDS, the median response duration is approximately only 24 months. Our data provide encouraging results concerning the benefits of using EPO alfa for the improvement of the quality of life, as patients treated with EPO showed higher overall survival, event-free survival rates and longer response durations than have been previously described in the literature.
Databáze: OpenAIRE
Externí odkaz: